belinostat
Phase 3- Indications
- Peripheral T-cell lymphoma, Cutaneous T-cell lymphoma, Ovarian cancer
Company intelligence / Profile preview
TopoTarget was a Danish biotechnology company specializing in the discovery and development of cancer therapies. Its lead product was belinostat, an HDAC inhibitor developed for hematological cancers and solid tumors. The company also marketed Savene®/Totect™ for anthracycline extravasation injuries. In addition to its own R&D pipeline, it engaged in multiple academic and industry collaborations. In July/August of 2014, TopoTarget merged with BioAlliance Pharma to form Onxeo S.A., ceasing independent operations.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on TopoTarget.